好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Identifying Falling Risk Factors Remotely in Multiple Sclerosis
Multiple Sclerosis
MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)
042

To evaluate fall risk in a well-phenotyped prospective multiple sclerosis (MS) cohort and analyze associations between falling and clinical, patient-reported, and remote activity metrics.

Falling is common in people with MS but tends to be under-ascertained and under-treated despite its substantial role in morbidity and disability progression.

Ninety-four people with MS who were able to walk >2 minutes with or without an assistive device were prospectively recruited. Clinic-based measures were recorded at study entry and 1-year later. Average daily step count (STEPS) was continuously recorded using a wrist-worn accelerometer (Fitbit Flex) and patient-reported outcomes (PROs), including the 12-Item MS Walking Scale (MSWS-12) and a fall survey, were completed at study entry, 1.5, 3, 6, 9, and 12 months.

Of 94 participants, 50 (53.2%) reported falling at least once over 1-year. Only 56% of patients who reported a fall on the study survey had clinical documentation of falling in the electronic medical record from routine care. ‘Fallers’ had greater disability [median EDSS 5.5 (IQR 4.0 – 6.0) versus 2.5 (IQR 1.5 - 4.0)], were more likely to have progressive MS (p=0.003), and took fewer STEPS (mean difference -1,979, p=0.007) than non-fallers. Stepwise regression revealed MSWS-12 to be the top remote predictor of future falls. The World Health Organization Disability Assessment Schedule, MFIS-5 (fatigue) and baseline STEPS were also found to be relevant fall predictors at surveys; 3, 6 and 12 months.

Falling is common in people with MS and is both under-reported and under-recognized in routine clinical care. Multimodal fall screening in clinic or remotely, including directly asking patients about prior falls, PROs (MSWS-12) and recognition of low STEPS on remote activity monitoring, may help improve patient care by identifying patients at greatest risk of falling and allow for timely intervention and referral to specialized physical rehabilitation services.

Authors/Disclosures
Valerie A. Block, DPTSc (University of California, San Francisco)
PRESENTER
Dr. Block has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. The institution of Dr. Block has received research support from National MS Society.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Riley Bove, MD, FAAN (University of California, San Francisco) Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme-Sanofi. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD-Serono. Dr. Bove has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cadenza. The institution of Dr. Bove has received research support from Biogen. The institution of Dr. Bove has received research support from Eli Lilly. The institution of Dr. Bove has received research support from Novartis. The institution of Dr. Bove has received research support from Roche Genentech.
Bruce A. Cree, MD, PhD, MAS, FAAN (UCSF, Multiple Sclerosis Center) The institution of Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neuron23. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Pharma. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal/Sandoz. Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. The institution of Dr. Cree has received research support from Genentech. The institution of Dr. Cree has received research support from Kyverna. Dr. Cree has received publishing royalties from a publication relating to health care.
Jeffrey M. Gelfand, MD, MS, FAAN (University of California, San Francisco) Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities.